MedTrace Logo

Safety and Efficacy of Liraglutide in Parkinson's Disease

NCT02953665 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2024-03-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the efficacy and safety of liraglutide in the treatment of patients with idiopathic Parkinson's disease (PD).

Conditions

  • Parkinson Disease

Interventions

DRUG

Liraglutide

Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg

DRUG

Placebo

Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg

Sponsors & Collaborators

  • Cure Parkinson's

    collaborator OTHER

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • Cedars-Sinai Medical Center

    lead OTHER

Principal Investigators

  • Michele Tagliati, MD · Cedars-Sinai Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-03
Primary Completion
2022-08-03
Completion
2022-08-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02953665 on ClinicalTrials.gov